

## CLINICAL CANCER RESEARCH

## TABLE OF CONTENTS

## HIGHLIGHTS

**2367** Selected Articles from This Issue

## SPECIAL FEATURES

## CCR Translations

**2369** **Eligibility in Cancer Clinical Research: The Intersection of Discovery, Generalizability, Beneficence, and Justice**

Bruce J. Giantonio

See related articles, p. 2394, 2400, 2408, 2416, 2424, and 2430

**2372** **Amplifying the Voice of the Whispering Cancer**

Neesha C. Dhani

See related article, p. 2549

**2375** **New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma**

Bradley A. McGregor and Guru P. Sonpavde

See related article, p. 2560

## CCR Drug Updates

**2378** **FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer**

Sonia Singh, Adnan A. Jaigirdar, Flora Mulkey, Joyce Cheng, Salaheldin S. Hamed, Yangbing Li, Jiang Liu, Hong Zhao, Anwar Goheer, Whitney S. Helms, Xing Wang, Rajiv Agarwal, Rajan Pragani, Kwadwo Korsah, Shenghui Tang, John Leighton, Atiqur Rahman, Julia A. Beaver, Richard Pazdur, Marc R. Theoret, and Harpreet Singh

## Review

**2383** **IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy**

Alvaro Teijeira, Saray Garasa, Maria C. Ochoa, Maria Villalba, Irene Olivera, Assunta Cirella, Iñaki Eguren-Santamaria, Pedro Berraondo, Kurt A. Schalper, Carlos E. de Andrea, Miguel F. Sanmamed, and Ignacio Melero

## Perspectives

**2394** **Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement**

Edward S. Kim, Thomas S. Uldrick, Caroline Schenkel, Suanna S. Bruinooge, R. Donald Harvey, Allison Magnuson, Alexander Spira, James L. Wade, Mark D. Stewart, Diana Merino Vega, Julia A. Beaver, Andrea M. Denicoff, Gwynn Ison, S. Percy Ivy, Suzanne George, Raymond P. Perez, Patricia A. Spears, William D. Tap, and Richard L. Schilsky

See related commentary, p. 2369

**2400** **Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group**

R. Donald Harvey, Kathryn F. Mileham, Vishal Bhatnagar, Jamie R. Brewer, Atiqur Rahman, Cassadie Moravek, Andrew S. Kennedy, Elizabeth A. Ness, E. Claire Dees, S. Percy Ivy, Scot W. Ebbinghaus, Caroline Schenkel, and Thomas S. Uldrick

See related commentary, p. 2369

**2408** **Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group**

Raymond U. Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, Suparna Wedam, Gwynn Ison, Sol Atienza, Peter De Porre, Tithi Biswas, Jamie N. Holloway, David S. Hong, Madison M. Wempe, Richard L. Schilsky, Edward S. Kim, and James L. Wade III

See related commentary, p. 2369

**2416** **Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group**

Alexander I. Spira, Mark D. Stewart, Suzanne Jones, Elaine Chang, Anitra Fielding, Nicole Richie, Laura S. Wood, Michael A. Thompson, Lee Jones, Abhilasha Nair, Brandon A. Mahal, and David E. Gerber

See related commentary, p. 2369

# TABLE OF CONTENTS

- 2424**    **Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group**  
Allison Magnuson, Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia Jalal, Stuart M. Lichtman, Paul G. Kluetz, Gary H. Lyman, Heidi D. Klepin, Mark E. Fleury, Brad Hirsch, Allen Melemed, Fernanda I. Arnaldez, Upal Basu Roy, Caroline Schenkel, Shimere Sherwood, and Elizabeth Garrett-Mayer  
See related commentary, p. 2369

- 2430**    **Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations**  
R. Donald Harvey, Suanna S. Bruinooge, Li Chen, Elizabeth Garrett-Mayer, Whitney Rhodes, Edward Stepanski, Thomas S. Uldrick, Gwynn Ison, Sean Khozin, Wendy S. Rubinstein, Caroline Schenkel, Robert S. Miller, George A. Komatsoulis, Richard L. Schilsky, and Edward S. Kim  
See related commentary, p. 2369

## CLINICAL TRIALS: TARGETED THERAPY

- 2435**    **A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)**  
Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia, David J. McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Jared S. Fowles, Daniel L. Gustafson, Melissa Plets, and Ian M. Thompson Jr
- 2442**    **A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study**  
Mariko D. DeWire, Christine Fuller, Olivia Campagne, Tong Lin, Haitao Pan, Tina Young Poussaint, Patricia A. Baxter, Eugene I. Hwang, Andrew Bukowinski, Kathleen Dorris, Lindsey Hoffman, Angela J. Waanders, Matthias A. Karajannis, Clinton F. Stewart, Arzu Onar-Thomas, Maryam Fouladi, and Ira J. Dunkel
- 2452**    **An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline *BRCA1/2* Mutation and Platinum-sensitive Recurrent Ovarian Cancer**  
Ning Li, Hualei Bu, Jihong Liu, Jianqing Zhu, Qi Zhou, Li Wang, Rutie Yin, Xiaohua Wu, Shuzhong Yao, Kangsheng Gu, Hui Zhang, Guiling Li, Hongming Pan, Qiang Wu, Ruifang An, Xinfeng Yang, Yaping Zhu, Xiaoping Wan, Wei Duan, Jianping Xiong, Hongyan Guo, Ge Lou, Jing Wang, Wenjing Hu, Xin Zhang, Yuanguang Meng, Ben Zhang, Yuting Wang, Quanren Wang, and Lingying Wu

- 2459**    **Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer**  
Michael Skwarski, Daniel R. McGowan, Elizabeth Belcher, Francesco Di Chiara, Dionisios Stavroulias, Mark McCole, Jennifer L. Derham, Kwun-Ye Chu, Eugene Teoh, Jagat Chauhan, Dawn O'Reilly, Benjamin H.L. Harris, Philip S. Macklin, Joshua A. Bull, Marcus Green, Gonzalo Rodriguez-Berriguete, Remko Prevo, Lisa K. Folkes, Leticia Campo, Petra Ferencz, Paula L. Croal, Helen Flight, Cathy Qi, Jane Holmes, James P.B. O'Connor, Fergus V. Gleeson, W. Gillies McKenna, Adrian L. Harris, Daniel Bulte, Francesca M. Buffa, Ruth E. Macpherson, and Geoff S. Higgins

## CLINICAL TRIALS: IMMUNOTHERAPY

- 2470**    **A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer**  
Arta M. Monjazeb, Anita Giobbie-Hurder, Ana Lako, Emily M. Thrash, Ryan C. Brennick, Katrina Z. Kao, Claire Manuszak, Ryan D. Gentzler, Anteneh Tesfaye, Salma K. Jabbour, Olatunji B. Alese, Osama E. Rahma, James M. Cleary, Elad Sharon, Harvey J. Mamon, May Cho, Howard Streicher, Helen X. Chen, Mansoor M. Ahmed, Adrian Mariño-Enríquez, Seunghye Kim-Schulze, Sacha Gnjjatic, Emanuel Maverakis, Alina I. Marusina, Alexander A. Merleev, Mariano Severgnini, Kathleen L. Pfaff, James Lindsay, Jason L. Weirather, Srinika Ranasinghe, Alexander Spektor, Scott J. Rodig, Stephen F. Hodi, and Jonathan D. Schoenfeld
- 2481**    **Intratatumoral Plasmid IL12 Expands CD8<sup>+</sup> T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti-PD-1 Therapy**  
**A C** Melinda L. Telli, Hiroshi Nagata, Irene Wapnir, Chaitanya R. Acharya, Kaitlin Zablotsky, Bernard A. Fox, Carlo B. Bifulco, Shawn M. Jensen, Carmen Ballesteros-Merino, Mai Hope Le, Robert H. Pierce, Erica Browning, Reneta Hermiz, Lauren Svenson, Donna Bannavong, Kim Jaffe, Jenny Sell, Kellie Malloy Foerter, David A. Canton, Christopher G. Twitty, Takuya Osada, H. Kim Lyerly, and Erika J. Crosby

# TABLE OF CONTENTS

## PRECISION MEDICINE AND IMAGING

- 2494** **Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers**  
Kelly L. Harms, Lili Zhao, Bryan Johnson, Xiaoming Wang, Shannon Carskadon, Nallasivam Palanisamy, Daniel R. Rhodes, Rahul Mannan, Josh N. Vo, Jae Eun Choi, May P. Chan, Douglas R. Fullen, Rajiv M. Patel, Javed Siddiqui, Vincent T. Ma, Steven Hrycaj, Scott A. McLean, Tasha M. Hughes, Christopher K. Bichakjian, Scott A. Tomlins, and Paul W. Harms
- 2505** **The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer**  
**A C** Paolo Manca, Salvatore Corallo, Adele Busico, Sara Lonardi, Francesca Corti, Carlotta Antoniotti, Letizia Procaccio, Matteo Clavarezza, Valeria Smiroldo, Gianluca Tomasello, Roberto Murialdo, Andrea Sartore-Bianchi, Patrizia Racca, Filippo Pagani, Giovanni Randon, Antonia Martinetti, Elisa Sottotetti, Federica Palermo, Federica Perrone, Elena Tamborini, Michele Prisciandaro, Alessandra Raimondi, Maria Di Bartolomeo, Federica Morano, and Filippo Pietrantonio
- 2515** **Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study**  
**A C** Yoshinori Kagawa, Elena Elez, Jesús García-Foncillas, Hideaki Bando, Hiroya Taniguchi, Ana Vivancos, Kiwamu Akagi, Ariadna García, Tadamichi Denda, Javier Ros, Tomohiro Nishina, Iosune Baraibar, Yoshito Komatsu, Davide Ciardiello, Eiji Oki, Toshihiro Kudo, Takeshi Kato, Takeharu Yamanaka, Josep Taberner, and Takayuki Yoshino
- 2523** **High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9**  
Shounak Majumder, William R. Taylor, Patrick H. Foote, Calise K. Berger, Chung Wah Wu, Douglas W. Mahoney, William R. Bamlet, Kelli N. Burger, Neil Postier, Jaime de la Fuente, Karen A. Doering, Graham P. Lidgard, Hatim T. Allawi, Gloria M. Petersen, Suresh T. Chari, David A. Ahlquist, and John B. Kisiel
- 2549** **Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer**  
Lara Paracchini, Luca Beltrame, Tommaso Grassi, Alessia Inglesi, Robert Fruscio, Fabio Landoni, Davide Ippolito, Martina Delle Marchette, Mariachiara Paderno, Marco Adorni, Marta Jaconi, Chiara Romualdi, Maurizio D'Incalci, Giulia Siravegna, and Sergio Marchini  
See related commentary, p. 2372
- 2560** **Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma**  
**A C** Jad Chahoud, Frederico O. Gleber-Netto, Barrett Z. McCormick, Priya Rao, Xin Lu, Ming Guo, Margaret B. Morgan, Randy A. Chu, Magaly Martinez-Ferrer, Agda Karina Eterovic, Curtis R. Pickering, and Curtis A. Pettaway  
See related commentary, p. 2375
- 2571** **A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors**  
Fyza Y. Shaikh, James R. White, Joell J. Gills, Taiki Hakozaki, Corentin Richard, Bertrand Routy, Yusuke Okuma, Mykhaylo Usyk, Abhishek Pandey, Jeffrey S. Weber, Jiyoung Ahn, Evan J. Lipson, Jarushka Naidoo, Drew M. Pardoll, and Cynthia L. Sears
- 2584** **Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer**  
Bruno V. Sinn, Sibylle Loibl, Claus A. Hansch, Dirk-Michael Zahm, Hans-Peter Sinn, Michael Untch, Karsten Weber, Thomas Karn, Clemens Becker, Frederik Marmé, Wolfgang D. Schmitt, Volkmar Müller, Christian Schem, Denise Treue, Elmar Stickeler, Frederik Klauschen, Nicole Burchardi, Jenny Furlanetto, Marion van Mackelenbergh, Peter A. Fasching, Andreas Schneeweiss, and Carsten Denkert
- 2592** **Circulating Protein Biomarkers for Use in Pancreatic Ductal Adenocarcinoma Identification**  
Sidsel C. Lindgaard, Zsófia Sztupinszki, Emil Maag, Inna M. Chen, Astrid Z. Johansen, Benny V. Jensen, Stig E. Bojesen, Dorte L. Nielsen, Carsten P. Hansen, Jane P. Hasselby, Kaspar R. Nielsen, Zoltan Szallasi, and Julia S. Johansen

## TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 2533** **Cell Type-specific Adaptive Signaling Responses to KRAS<sup>G12C</sup> Inhibition**  
Hitendra S. Solanki, Eric A. Welsh, Bin Fang, Victoria Izumi, Lancia Darville, Brandon Stone, Ryan Franzese, Sandip Chavan, Fumi Kinose, Denis Imbody, John M. Koomen, Uwe Rix, and Eric B. Haura

# TABLE OF CONTENTS

**2604** ***KRAS*<sup>G12C</sup> Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma**

Gregory D. Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sanchez-Vega, Yuan Liu, James G. Connolly, Yonina R. Murciano-Goroff, Matthew J. Bott, Prasad S. Adusumilli, Daniela Molena, Gaetano Rocco, Valerie W. Rusch, Smita Sihag, Sandra Misale, Rona Yaeger, Alexander Drilon, Kathryn C. Arbour, Gregory J. Riely, Neal Rosen, Piro Lito, Haiying Zhang, David C. Lyden, Charles M. Rudin, David R. Jones, Bob T. Li, and James M. Isbell

**2613** **Clinicopathologic and Genomic Analysis of *TP53*-Mutated Endometrial Carcinomas**

Amir Momeni-Boroujeni, Wissam Dahoud, Chad M. Vanderbilt, Sarah Chiang, Rajmohan Murali, Eric V. Rios-Doria, Kaled M. Alektiar, Carol Aghajanian, Nadeem R. Abu-Rustum, Marc Ladanyi, Lora H. Ellenson, Britta Weigelt, and Robert A. Soslow

**2624** **G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma**

Gregory M. Kelly, Fares Al-Ejeh, Robert McCuaig, Francesco Casciello, Nabilah Ahmad Kamal, Blake Ferguson, Antonia L. Pritchard, Sayed Ali, Ines P. Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Sudha Rao, Nicholas K. Hayward, Frank Gannon, and Jason S. Lee

**2636** **Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance**

Phillip M. Galbo Jr, Xingxing Zang, and Deyou Zheng

**2648** **Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer**

Xian Wang, Jamunarani Veeraraghavan, Chia-Chia Liu, Xixi Cao, Lanfang Qin, Jin-Ah Kim, Ying Tan, Suet Kee Loo, Yiheng Hu, Ling Lin, Sanghoon Lee, Martin J. Shea, Tamika Mitchell, Shunqiang Li, Matthew J. Ellis, Susan G. Hilsenbeck, Rachel Schiff, and Xiao-Song Wang

## CORRECTIONS

**2663** **Correction: A Virus-infected, Reprogrammed Somatic Cell-derived Tumor Cell (VIREST) Vaccination Regime can Prevent Initiation and Progression of Pancreatic Cancer**

Shuangshuang Lu, Zhe Zhang, Pan Du, Louisa S. Chard, Wenli Yan, Margueritte El Khouri, Zhizhong Wang, Zhongxian Zhang, Yongchao Chu, Dongling Gao, Qinxian Zhang, Lirong Zhang, Ai Nagano, Jun Wang, Claude Chelala, Jing Liu, Jiekai Chen, Pentao Liu, Yunshu Dong, Shengdian Wang, Xiaozhu Li, Jianzeng Dong, Nick R. Lemoine, Duanqing Pei, and Yaohe Wang

**2664** **Correction: PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition**

Xin Chen, Ri-Xin Chen, Wen-Su Wei, Yong-Hong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gang-Jun Yuan, Si-Liang Chen, Sheng-Jie Guo, Kang-Hua Xiao, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, and Dan Xie

## EDITOR'S NOTES

**2665** **Editor's Note: Epigenetic Modifications of *RASSF1A* Gene through Chromatin Remodeling in Prostate Cancer**

Ken Kawamoto, Steven T. Okino, Robert F. Place, Shinji Urakami, Hiroshi Hirata, Nobuyuki Kikuno, Toshifumi Kawakami, Yuichiro Tanaka, Deepa Pookot, Zhong Chen, Shahana Majid, Hideki Enokida, Masayuki Nakagawa, and Rajvir Dahiya


**AC** AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

# TABLE OF CONTENTS

## ABOUT THE COVER

The cover shows an on-treatment biopsy taken from a patient with metastatic microsatellite stable colorectal cancer treated with combined PD-L1/CTLA-4 inhibition and targeted radiotherapy to a liver metastasis. Multiplex immunofluorescence staining demonstrates increased infiltration of CD8<sup>+</sup>(*white*)/PD-1<sup>+</sup>(*green*)/Ki-67<sup>+</sup>(*red*) cells with treatment. Cytokeratin (*purple*) highlights malignant cells. For details, see the article by Monjazeb and colleagues on page 2470 of this issue.



# Clinical Cancer Research

**27 (9)**

*Clin Cancer Res* 2021;27:2367-2665.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/27/9>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/27/9>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.